The fluorescence intensity of commonly employed EV-specific biomarkers (CD9, CD63 and CD81) in the HC group did not differ significantly between the train and test sets, confirming the data stability of the CRC-EVArray platform (Supplemental Fig 1B-E). This evidence concerns the gene CD63 and colorectal carcinoma.